麗珠集團(000513.SZ):注射用艾普拉唑鈉納入國家醫保目錄
格隆匯11月28日丨麗珠集團(000513.SZ)公佈,2019年11月28日,國家醫療保障局發佈了《關於將2019年談判藥品納入
<國家基本醫療保險、工傷保險和生育保險藥品目錄>
乙類範圍的通知》(醫保發〔2019〕65號)。公司注射用艾普拉唑鈉被納入《醫保目錄》“協議期內談判藥品部分”,且公司(乙方)與國家醫療保障局醫療保障事業管理中心(甲方)就注射用艾普拉唑鈉納入《醫保目錄》有關事項簽署了《2019年國家醫保藥品目錄談判准入及支付標準協議》。
國家基本醫療保險、工傷保險和生育保險藥品目錄>雙方約定的藥品醫保支付標準有效期為2020年1月1日至2021年12月31日。
該藥品通用名為注射用艾普拉唑鈉,商品名為壹麗安,醫保支付標準:156元(10mg/支),適用於治療消化性潰瘍出血。根據IQVIA數據,此次納入《醫保目錄》的公司獨家品種注射用艾普拉唑鈉於2018年1月獲批生產,2018年度銷售額為1081.91萬元;2019年1-9月銷售額為5684.10萬元,約佔國內PPI注射劑銷售總額的0.48%。
此次公司注射用艾普拉唑鈉被納入《醫保目錄》,將有利於該產品的市場推廣及未來銷售,將對公司的經營業績產生積極影響。因新版《醫保目錄》於2020年1月1日起正式執行,不會對公司本報告期的經營業績構成重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.